Interventions for valvular disease and heart failure
Impact of chronic kidney disease on outcomes after percutaneous mitral valve repair with the MitraClip system: insights from the GRASP registry
EuroIntervention 2016;11:e1649-e1657 published online e-edition April 2016. DOI: 10.4244/EIJV11I14A316
Yohei Ohno1,2, MD; Guilherme F. Attizzani1,3, MD; Davide Capodanno1,4, MD, PhD; Marco Barbanti1, MD; Stefano Cannata1, MD; Fabio Dipasqua1, MD; Sebastiano Immé1, MD; Margherita Ministeri1, MD; Anna Caggegi1, MD; Anna M. Pistritto1, MD; Marta Chiarandà1, MD; Giuseppe Ronsivalle1, MD; Sandra Giaquinta1, MD; Sarah Mangiafico1, MD; Salvatore Scandura1, MD; Piera Capranzano1,4, MD, PhD; Corrado Tamburino1,4, MD, PhD; Carmelo Grasso1*, MD
1. Department of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; 2. Department of Cardiology, Tokai University School of Medicine, Isehara, Japan; 3. The Valve and Structural Heart Intervention Center, Harrington Heart and Vascular
Aims: Our aim was to evaluate the impact of baseline chronic kidney disease (CKD) on clinical outcomes after percutaneous edge-to-edge mitral valve repair (PMVR).
